IBM Integration Bus Manufacturing Pack prior 1.0.0.0 cross site scripting
| CVSS Meta Temp Score | Current Exploit Price (≈) | CTI Interest Score |
|---|---|---|
| 4.1 | $0-$5k | 0.00 |
Summary
A vulnerability has been found in IBM Integration Bus Manufacturing Pack and classified as problematic. Affected by this vulnerability is an unknown functionality. The manipulation leads to cross site scripting. This vulnerability is documented as CVE-2014-4820. The attack can be initiated remotely. There is not any exploit available. The affected component should be upgraded.
Details
A vulnerability, which was classified as problematic, has been found in IBM Integration Bus Manufacturing Pack. This issue affects an unknown part. The manipulation with an unknown input leads to a cross site scripting vulnerability. Using CWE to declare the problem leads to CWE-79. The product does not neutralize or incorrectly neutralizes user-controllable input before it is placed in output that is used as a web page that is served to other users. Impacted is integrity. The summary by CVE is:
Cross-site scripting (XSS) vulnerability in IBM Integration Bus Manufacturing Pack 1.x before 1.0.0.1 allows remote attackers to inject arbitrary web script or HTML via unspecified vectors.
The weakness was released 09/18/2014 (Website). It is possible to read the advisory at xforce.iss.net. The identification of this vulnerability is CVE-2014-4820 since 07/09/2014. The attack may be initiated remotely. No form of authentication is needed for a successful exploitation. It demands that the victim is doing some kind of user interaction. The technical details are unknown and an exploit is not publicly available. The attack technique deployed by this issue is T1059.007 according to MITRE ATT&CK.
It is declared as highly functional.
Upgrading to version 1.0.0.0 eliminates this vulnerability.
The vulnerability is also documented in the databases at X-Force (95457) and SecurityFocus (BID 69878†). Statistical analysis made it clear that VulDB provides the best quality for vulnerability data.
Product
Vendor
Name
License
Website
- Vendor: https://www.ibm.com/
CPE 2.3
CPE 2.2
CVSSv4
VulDB Vector: 🔍VulDB Reliability: 🔍
CVSSv3
VulDB Meta Base Score: 4.3VulDB Meta Temp Score: 4.1
VulDB Base Score: 4.3
VulDB Temp Score: 4.1
VulDB Vector: 🔍
VulDB Reliability: 🔍
CVSSv2
| AV | AC | Au | C | I | A |
|---|---|---|---|---|---|
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| Vector | Complexity | Authentication | Confidentiality | Integrity | Availability |
|---|---|---|---|---|---|
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
VulDB Base Score: 🔍
VulDB Temp Score: 🔍
VulDB Reliability: 🔍
NVD Base Score: 🔍
Exploiting
Class: Cross site scriptingCWE: CWE-79 / CWE-94 / CWE-74
CAPEC: 🔍
ATT&CK: 🔍
Physical: No
Local: No
Remote: Yes
Availability: 🔍
Status: Highly functional
EPSS Score: 🔍
EPSS Percentile: 🔍
Price Prediction: 🔍
Current Price Estimation: 🔍
| 0-Day | Unlock | Unlock | Unlock | Unlock |
|---|---|---|---|---|
| Today | Unlock | Unlock | Unlock | Unlock |
Threat Intelligence
Interest: 🔍Active Actors: 🔍
Active APT Groups: 🔍
Countermeasures
Recommended: UpgradeStatus: 🔍
0-Day Time: 🔍
Upgrade: Integration Bus Manufacturing Pack 1.0.0.0
Timeline
07/09/2014 🔍09/16/2014 🔍
09/18/2014 🔍
09/18/2014 🔍
03/26/2015 🔍
03/17/2018 🔍
Sources
Vendor: ibm.comAdvisory: xforce.iss.net
Status: Confirmed
Confirmation: 🔍
CVE: CVE-2014-4820 (🔍)
GCVE (CVE): GCVE-0-2014-4820
GCVE (VulDB): GCVE-100-71291
X-Force: 95457 - IBM Integration Bus Manufacturing pack cross-site scripting
SecurityFocus: 69878 - IBM Integration Bus Manufacturing Pack CVE-2014-4820 Unspecified Cross Site Scripting Vulnerability
Entry
Created: 03/26/2015 15:08Updated: 03/17/2018 11:21
Changes: 03/26/2015 15:08 (47), 03/17/2018 11:21 (8)
Complete: 🔍
Cache ID: 216::103
Statistical analysis made it clear that VulDB provides the best quality for vulnerability data.
No comments yet. Languages: en.
Please log in to comment.